ERBB2 and cancer: In its phase II study carried out in 43 locally advanced or metastatic HER2+ urothelial carcinoma patients, RC48 was promising in anti HER2+ cancer with a 51.2% ORR, a median 6.9 months of progression-free survival (PFS) and 13.9 months of overall survival (OS).